Veristat supports the battle against rare cancers by participating in the Cycle for Survival
For Immediate Release
Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program
September 10, 2013 - Veristat, a leading,...
Veristat and Molecular Templates Inc. enter into Preferred Provider Agreement for...
For Immediate Release
Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™
Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid
Variance Development Partners Makes a Growth Investment in Veristat
Investment Will Enable Veristat to Further Enhance its Market Leadership Position and Provide Resources for Growth
Veristat, a ...